{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021512","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.029051+00:00","generated_at":"2026-06-22T08:56:17.641719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023","bullets":["Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.","Cash & equivalents $269.5M as of Sep 30, 2022; runway into H2 2025.","R&D expenses $27.9M and G&A $8.2M, both essentially flat year-over-year.","Portfolio updates across autoimmune, neurodegeneration and ophthalmology franchises planned for Jan 2023.","ANX005 HD Phase 2 data shows reduced neuroinflammation; regulator engagement by year-end; ANX007 GA Phase 2 data expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021512","json":"https://secwatch.observer/filing/0000950170-22-021512.json","markdown":"https://secwatch.observer/filing/0000950170-22-021512.md","text":"https://secwatch.observer/filing/0000950170-22-021512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/0000950170-22-021512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/annx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:56:17.641719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88989638b36c17ea2f3875c21eee8dc4ddf5d019","claim":"Annexon, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022, EPS $0.51 per share.","evidence_excerpt":"Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported third quarter 2022 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/0000950170-22-021512-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022"},{"label":"EPS","value":"$0.51 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}